Aradigm Corporation (NASDAQ:ARDM) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 23, 2016
Having a price of $6.50, Aradigm Corporation (NASDAQ:ARDM) traded 4.00% higher on the day. With the last stock price close up 44.55% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Aradigm Corporation has recorded a 50-day average of $4.71 and a two hundred day average of $4.50. Volume of trade was up over the average, with 39,689 shares of ARDM changing hands over the typical 8,317
Zacks Investment Research has downgraded Aradigm Corporation (NASDAQ:ARDM) to Hold in a statement released on 9/23/2016.
On 8/24/2016, Zacks Investment Research released a statement about Aradigm Corporation (NASDAQ:ARDM) upped the target price from $0.00 to $5.25 that suggested an upside of 0.15%.
With a total market value of $0, Aradigm Corporation has with a one year low of $2.60 and a one year high of $7.65 .
More About Aradigm Corporation (NASDAQ:ARDM)
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.